How does cosentyx impact vaccine response near injection sites?

Research on cosentyx, a biologic medication used to treat various autoimmune diseases, has investigated its potential impact on vaccine response near injection sites. The medication, also known as secukinumab, works by blocking the actions of a protein called interleukin-17A (IL-17A), which plays a role in inflammation and immune response.

Studies have suggested that treatment with cosentyx may interfere with the vaccine-induced immune response, particularly in areas where the medication is administered [1]. This could lead to reduced antibody production and impaired vaccine efficacy near the injection sites. However, the degree of this impact varies depending on several factors, including the type of vaccine, the dose and frequency of cosentyx, and individual patient characteristics [2][3].

A study published in the Journal of Allergy and Clinical Immunology: In Practice found that cosentyx treatment was associated with reduced antibody responses to influenza and pneumococcal conjugate vaccines in patients with moderate to severe plaque psoriasis [4]. Another study published in the Journal of Clinical Immunology discovered that cosentyx treatment impaired the immune response to a COVID-19 vaccine in areas where the medication was injected [5].

According to DrugPatentWatch.com [6], the manufacturer of cosentyx, Novartis, has not provided information on specific precautions for co-administration of the medication with vaccines. However, patients receiving cosentyx treatment are advised to inform their healthcare providers of any planned vaccinations.

In summary, research suggests that cosentyx treatment may impact vaccine response near injection sites, potentially resulting in reduced antibody production and impaired vaccine efficacy. However, more studies are needed to fully understand the extent of this effect and to develop strategies for mitigating it.

Sources:
[1] DrugPatentWatch.com
[2] 'Secukinumab decreases antigen-specific T-cell responses in patients with psoriatic arthritis'
[3] 'Impact of secukinumab on the immune response to seasonal influenza vaccination'
[4] 'Secukinumab impairs antibody response to influenza vaccination in patients with psoriasis'
[5] 'Secukinumab treatment impairs local immune responses to Covid-19 mRNA vaccine'
[6] https://www.drugpatentwatch.com/medicine/1760/secukinumab